Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | IARS1 | P41252 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 2/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14176118 | 1.00 | SMYD2 (0.35) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL5449704 | 0.94 | SMYD2 (0.38) | SMYD2ADORA1SLC6A2CYP3A4HTT | |
| SCHEMBL5473045 | 0.94 | SMYD2 (0.38) | SMYD2ADORA1SLC6A2CYP3A4HTT | |
| SCHEMBL1842898 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL16576331 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL17822565 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL5983168 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL1842894 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL19764252 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 | |
| SCHEMBL28637106 | 0.88 | SMYD2 (0.36) | SMYD2SLC5A2ADORA1SLC6A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | SMYD2 2848/4885SLC5A2 208/4885ADORA1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.